27

FEB

25

The Drug Cell : A new french alliance to redefine cell therapies

The French company “The Drug Cell” (TDC) has just been officially created, marking a decisive step forward for the European cell therapy sector.

Institute for Stem cell Therapy and Exploration of Monogenic diseases

In 2025, advancing research on rare and ultra-rare monogenic diseases requires the mobilization of significant human and technological resources. Within I-Stem, we are all mobilized around this common objective.

80

Between scientists and support functions, 80 people currently work at I-Stem.

Teams at the service of ambitious therapeutic objectives

Reasearch
teams

I-Stem brings together within its research teams the expertise and know-how of researchers, teacher-researchers, engineers and technicians. Retinopathies, genodermatoses, Limb-girdle muscular dystrophies, neuromuscular diseases & Myelinated fibers are part of our main scientific themes.

Triails
clinics

Clinical trials are a crucial step in the development of treatments for any pathology. I-Stem is the sponsor of several trials and supports others through partnerships.

stemCARE
Technology plateform

Excellent research requires state-of-the-art equipment. I-Stem is equipped with technological platforms allowing its research teams to optimize their fundamental, pre-clinical and clinical research projects.

News

  • News
  • Publications
Press release

27 February 2025

The French company “The Drug Cell” (TDC) has just been officially created, marking a decisive step forward for the European cell therapy sector.

Press release

16 January 2025

For the 2024 edition of its call for proposals, GIS IBiSA has defined several priority themes, including pluripotent stem cells.
Among the structures specialized in this field, the stemCARE technology platform has been selected for labeling.

Event

20 September 2024

Pr HÉNON Philippe will present a seminar at I-Stem on September 26, 2024, entitled: CD34+ cells and Very Small Embryonic-Like stem cells (VSELs) : Clinical applications in cardiology.

Retinopathies.

01 November 2025

The outer blood-retinal barrier (oBRB) is compromised in several retinal pathologies, such as age-related macular degeneration affecting over 200 million people worldwide. This 200-350 μm thick tissue includes the retinal pigment epithelium (RPE), the Bruch's membrane, and the vascularized choroi...

LGMDs.NGS.

14 April 2025

Glycogen storage disease type III (GSDIII) is a rare genetic disorder leading to abnormal glycogen storage in the liver and skeletal muscle. In this study, we conducted a comparative gene expression analysis of several in vitro and in vivo models and identified galectin-3 as a potential biomarker...

I-Stem is a member of the Institute of Biotherapies for Rare Diseases created by the AFM - Telethon